Business Description
Biofrontera AG
ISIN : DE0006046113
Compare
Compare
Traded in other countries / regions
B8F.Germany0DOL.UKBFFTF.USA IPO Date
2007-12-28Description
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.81 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | 14.79 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -9.23 | |||||
| Beneish M-Score | -7.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -13.1 | |||||
| 3-Year EPS without NRI Growth Rate | -70.4 | |||||
| 3-Year FCF Growth Rate | 51.8 | |||||
| 3-Year Book Growth Rate | 15.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.73 | |||||
| 9-Day RSI | 44.91 | |||||
| 14-Day RSI | 45.63 | |||||
| 6-1 Month Momentum % | -37.82 | |||||
| 12-1 Month Momentum % | -72.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.72 | |||||
| Quick Ratio | 1.1 | |||||
| Cash Ratio | 0.37 | |||||
| Days Inventory | 324.54 | |||||
| Days Sales Outstanding | 12.63 | |||||
| Days Payable | 123.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.8 | |||||
| Shareholder Yield % | 5.24 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.07 | |||||
| Operating Margin % | 2.17 | |||||
| Net Margin % | -30.06 | |||||
| FCF Margin % | -17.03 | |||||
| ROE % | -51.01 | |||||
| ROA % | -30.67 | |||||
| ROIC % | 3.79 | |||||
| ROC (Joel Greenblatt) % | -245.21 | |||||
| ROCE % | -40.38 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.68 | |||||
| PB Ratio | 1.43 | |||||
| Price-to-Tangible-Book | 1.64 | |||||
| EV-to-EBIT | -2.5 | |||||
| EV-to-EBITDA | -2.5 | |||||
| EV-to-Revenue | 0.66 | |||||
| EV-to-Forward-Revenue | 1.57 | |||||
| EV-to-FCF | -3.63 | |||||
| Price-to-Projected-FCF | 6.56 | |||||
| Price-to-Median-PS-Value | 0.06 | |||||
| Price-to-Net-Current-Asset-Value | 3.64 | |||||
| Earnings Yield (Greenblatt) % | -40.05 | |||||
| FCF Yield % | -23.29 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers